Non-small cell lung cancer biomarkers and targeted therapy - two faces of the same coin fostered by nanotechnology

References

• World Health Organization. Lung Cancer. International angency for Research on Cancer; GLOBOCAN 2012: estimated cancer incidence, mortality, and prevalence worldwide in 2012. Available from: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.
   Google Scholar
• Chen Z, Fillmore CM, Hammerman PS, et al. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer. 2014;14(8):535–546.
   PubMed Web of Science ®Google Scholar
• Rose-James A, Tt S. Molecular markers with predictive and prognostic relevance in lung cancer. Lung Cancer Int. 2012;2012:1–12.
   Google Scholar
• Rosell R, Bivona TG, Karachaliou N. Genetics and biomarkers in personalisation of lung cancer treatment. Lancet. 2013;382(9893):720–731.
   PubMed Web of Science ®Google Scholar
• Wu K, Huang RS, House L, et al. Next-generation sequencing for lung cancer. Futur Oncol. 2013;9:1323–1336.
   PubMed Web of Science ®Google Scholar
• Raparia K, Villa C, DeCamp MM, et al. Molecular profiling in non-small cell lung cancer: a step toward personalized medicine. Arch Pathol Lab Med. 2013;137:481–491.
   PubMed Web of Science ®Google Scholar
• Pikor LA, Ramnarine VR, Lam S, et al. Genetic alterations defining NSCLC subtypes and their therapeutic implications. Lung Cancer. 2013;82(2):179–189.
   PubMed Web of Science ®Google Scholar
• Navani N, Nankivell M, Lawrence DR, et al. Lung cancer diagnosis and staging with endobronchial ultrasound-guided transbronchial needle aspiration compared with conventional approaches: an open-label, pragmatic, randomised controlled trial. Lancet Respir Med. 2015;3:282–289.
   PubMed Web of Science ®Google Scholar
• Rivera P, Detterbeck F, Mehta A. Diagnosis of Lung Cancer. Chest J. 2003;123:129–136.
   Web of Science ®Google Scholar
• Dietel M, Bubendorf L, Dingemans AC, et al. Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group. Thorax. 2015;0:1–8.
   Google Scholar
• Smith RA, Manassaram-Baptiste D, Brooks D, et al. Cancer screening in the United States, 2015: a review of current American Cancer Society Guidelines and current issues in cancer screening robert. A Cancer J Clin. 2015;65(1):30–54.
   PubMed Web of Science ®Google Scholar
• Jiang T, Ren S, Zhou C. Role of circulating-tumor DNA analysis in non-small cell lung cancer. Lung Cancer. 2015;90(2):128–134.
   PubMed Web of Science ®Google Scholar
• Rolfo C, Castiglia M, Hong D, et al. Liquid biopsies in lung cancer: the new ambrosia of researchers. Biochim Biophys Acta. 2014;1846:539–546.
   PubMed Web of Science ®Google Scholar
• Minguet J, Smith KH, Bramlage CP, et al. Targeted therapies for treatment of renal cell carcinoma: recent advances and future perspectives. Int J Cancer. 2015; published online 4 November 2015. doi:10.1002/ijc.29915.
   PubMedGoogle Scholar
• McCloskey P, Balduyck B, Van Schil PE, et al. Radical treatment of non-small cell lung cancer during the last 5 years. Eur J Cancer. 2013;49(7):1555–1564.
   PubMed Web of Science ®Google Scholar
• Carbognin L, Pilotto S, Milella M, et al. Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers. PLoS One. 2015;10:1–16.
   Web of Science ®Google Scholar
• Scagliotti GV, Novello S, Rapetti S, et al. Current state-of-the-art therapy for advanced squamous cell lung cancer. Torino: ASCO Educational Book; 2013.
   Google Scholar
• Gentzler RD, Johnson ML. Complex decisions for first-line and maintenance treatment of advanced wild-type non-small cell lung cancer. Oncologist. 2015;20:1–8.
   PubMed Web of Science ®Google Scholar
• Babu A, Templeton AK, Munshi A, et al. Nanoparticle-based drug delivery for therapy of lung cancer: progress and challenges. J Nanomater. 2013;2013:1–11.
   Web of Science ®Google Scholar
• West L, Vidwans SJ, Campbell NP, et al. A novel classification of lung cancer into molecular subtypes. PLoS One. 2012;7:1–11.
   Web of Science ®Google Scholar
• Ogunleye F, Ibrahim M, Stender M, et al. Epidermal growth factor receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer. Am J Hematol/Oncol. 2015;11:16–25.
   Google Scholar
• In GK, Nieva J. Emerging chemotherapy agents in lung cancer: nanoparticle therapeutics for non-small cell lung cancer. Transl Lung Cancer Res. 2015;4:340–355.
   Google Scholar
• Fan T, Song Y-J, Liu X-L. Adenocarcinoma of the lung with concomitant ALK fusion gene and EGFR gene mutation: a case report and literature review. Mol Clin Oncol. 2015;4:203–205.
   PubMedGoogle Scholar
• Stinchcombe TE, Borghaei H, Barker SS, et al. Pemetrexed with platinum combination as a backbone for targeted therapy in non–small-cell lung cancer. Clin Lung Cancer. 2016;17:1–9.
   PubMed Web of Science ®Google Scholar
• Salgia R, Hensing T, Campbell N, et al. Personalized treatment of lung cancer. Semin Oncol. 2011;38:274–283.
   PubMed Web of Science ®Google Scholar
• WHO. International programme on chemical safety biomarkers in risk assessment: validity and validation. [2001]. Available from: http://www.inchem.org/documents/ehc/ehc/ehc222.htm.
   Google Scholar
• Strimbu K, Tavel JA. What are biomarkers? Curr Opin HIV AIDS. 2010;5:463–466.
   PubMed Web of Science ®Google Scholar
• Bohunicky B, Mousa SA. Biosensors: the new wave in cancer diagnosis. Nanotechnol Sci Appl. 2011;4:1–10.
   Google Scholar
• Kisluk J, Ciborowski M, Niemira M, et al. Proteomics biomarkers for non-small cell lung cancer. J Pharm Biomed Anal. 2014;101:40–49.
   PubMed Web of Science ®Google Scholar
• Gainor JF, Longo DL, Chabner BA. Pharmacodynamic biomarkers: falling short of the mark? Clin Cancer Res. 2014;20:2587–2594.
   PubMed Web of Science ®Google Scholar
• Kumar M, Ernani V, Owonikoko TK. Biomarkers and targeted systemic therapies in advanced non-small cell lung cancer. Mol Aspects Med. 2015;45:55–66.
   PubMed Web of Science ®Google Scholar
• Sung H-J, Cho J-Y. Biomarkers for the lung cancer diagnosis and their advances in proteomics. BMB Rep. 2008;41(9):615–625.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yang Q, Wang S. MicroRNAs: a new key in lung cancer. Cancer Chemother Pharmacol. 2014;74(6):1105–1111.
   PubMed Web of Science ®Google Scholar
• Zhao W, Zhao J, Zhang L, et al. Serum miR-21 level: a potential diagnostic and prognostic biomarker for non-small cell lung cancer. Int J Clin Exp Med. 2015;8:14759–14763.
   PubMed Web of Science ®Google Scholar
• Tang Q, Ni Z, Cheng Z, et al. Three circulating long non-coding RNAs act as biomarkers for predicting NSCLC. Cell Physiol Biochem. 2015;37(3):1002–1009.
   PubMed Web of Science ®Google Scholar
• Ludovini V, Bianconi F, Pistola L, et al. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2011;6(4):707–715.
   PubMed Web of Science ®Google Scholar
• Hanai J-I, Doro N, Sasaki AT, et al. Inhibition of lung cancer growth: ATP citrate lyase knockdown and statin treatment leads to dual blockade of mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3-kinase (PI3K)/AKT pathways. J Cell Physiol. 2013;227:1709–1720.
   Web of Science ®Google Scholar
• Toulany M, Dittmann K, Krüger M, et al. Radioresistance of K-Ras mutated human tumor cells is mediated through EGFR-dependent activation of PI3K-AKT pathway. Radiother Oncol. 2005;76:143–150.
   PubMed Web of Science ®Google Scholar
• Cooper WA, Lam DCL, O’Toole SA, et al. Molecular biology of lung cancer. J Thorac Dis. 2013;5:479–490.
   PubMedGoogle Scholar
• Berge EM, Doebele RC. Targeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor. Semin Oncol. 2014;41:110–125.
   PubMed Web of Science ®Google Scholar
• Sudhir P-R, Hsu C-L, Wang M-J, et al. Phosphoproteomics identifies oncogenic Ras signaling targets and their involvement in lung adenocarcinomas. PLoS One. 2011;6:1–10.
   Web of Science ®Google Scholar
• Massuti B, Sanchez JM, Hernando-trancho F, et al. Are we ready to use biomarkers for staging, prognosis and treatment selection in early-stage non-small-cell lung cancer? Transl Lung Cancer Res. 2013;2:208–221.
   PubMedGoogle Scholar
• Neal JW, Sequist LV. Exciting new targets in lung cancer therapy: ALK, IGF-1R, HDAC, and Hh. Curr Treat Options Oncol. 2010;11(1–2):36–44.
   PubMed Web of Science ®Google Scholar
• Carnio S, Novello S, Papotti M, et al. Prognostic and predictive biomarkers in early stage non-small cell lung cancer: tumor based approaches including gene signatures. Transl Lung Cancer Res. 2013;2:372–381.
   PubMedGoogle Scholar
• Sattler M, Hasina R, Reddy MM, et al. The role of the c-Met pathway in lung cancer and the potential for targeted therapy. Ther Adv Med Oncol. 2011;3:171–184.
   PubMedGoogle Scholar
• Ma PC, Jagadeeswaran R, Jagadeesh S, et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non – small cell lung cancer. Cancer Res. 2005;65:1479–1488.
   PubMed Web of Science ®Google Scholar
• Kanteti R, Yala S, Ferguson MK, et al. MET, HGF, EGFR, and PXN gene copy number in lung cancer using DNA extracts from FFPE archival samples and prognostic significance. J Environ Pathol Toxicol Oncol. 2009;28(2):89–98.
   PubMed Web of Science ®Google Scholar
• Lawrence RE, Salgia R. MET molecular mechanisms and therapies in lung cancer. Cell Adhes Migr. 2010;4:146–152.
   PubMed Web of Science ®Google Scholar
• Ma PC, Kijima T, Maulik G, et al. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res. 2003;63:6272–6281.
   PubMed Web of Science ®Google Scholar
• Sadiq AA, Salgia R. MET as a possible target for non-small-cell lung cancer. J Clin Oncol. 2013;31:1089–1096.
   PubMed Web of Science ®Google Scholar
• Sierra JR, Tsao M. c-MET as a potential therapeutic target and biomarker in cancer. Ther Adv Med Oncol. 2011;3:21–35.
   PubMedGoogle Scholar
• Al-Saad S, Donnem T, Al-Shibli K. Diverse prognostic roles of Akt isoforms, PTEN and PI3K in tumor epithelial cells and stromal compartment in non-small cell lung cancer. Anticancer Res. 2009;29:4175–4183.
   PubMed Web of Science ®Google Scholar
• Mason CS, Springer CJ, Cooper RG, et al. Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation. Embo J. 1999;18:2137–2148.
   PubMed Web of Science ®Google Scholar
• Sánchez-Torres JM, Viteri S, Molina MA, et al. BRAF mutant non-small cell lung cancer and treatment with BRAF inhibitors. Transl Lung Cancer Res. 2013;2:244–250.
   PubMedGoogle Scholar
• Paik PK, Arcila ME, Fara M, et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol. 2011;29:2046–2051.
   PubMed Web of Science ®Google Scholar
• Boyle TA, Masago K, Ellison KE, et al. ROS1 Immunohistochemistry among major genotypes of non-small-cell lung cancer. Clin Lung Cancer. 2015;16:106–111.
   PubMed Web of Science ®Google Scholar
• Rothschild S. Targeted therapies in non-small cell lung cancer-beyond EGFR and ALK. Cancers. 2015;7:930–949.
   PubMed Web of Science ®Google Scholar
• Puig De La Bellacasa R, Karachaliou N, Estrada-Tejedor R, et al. ALK and ROS1 as a joint target for the treatment of lung cancer: a review. Transl Lung Cancer Res. 2013;2:72–86.
   PubMedGoogle Scholar
• Ge L, Shi R. Progress of EGFR-TKI and ALK/ROS1 inhibitors in advanced non-small cell lung cancer. Int J Clin Exp Med. 2015;8:10330–10339.
   PubMed Web of Science ®Google Scholar
• Solomon B, Maccallum P, Centre C, et al. Validating ROS1 rearrangements as a therapeutic target in non – small-cell lung cancer. J Clin Oncol. 2015;33:1–4.
   PubMed Web of Science ®Google Scholar
• Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011;12:175–180.
   PubMed Web of Science ®Google Scholar
• Kohno T, Ichikawa H, Totoki Y, et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med. 2012;18:375–377.
   PubMed Web of Science ®Google Scholar
• Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012;18:378–381.
   PubMed Web of Science ®Google Scholar
• Behrens C, Lin HY, Lee JJ, et al. Immunohistochemical expression of basic fibroblast growth factor and fibroblast growth factor receptors 1 and 2 in the pathogenesis of lung cancer. Clin Cancer Res. 2008;14:6014–6022.
   PubMed Web of Science ®Google Scholar
• Fischer H, Taylor N, Allerstorfer S, et al. Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition. Mol Cancer Ther. 2008;7:3408–3419.
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Spigel DR, Chen D, et al. Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer. J Clin Oncol. 2011;29:4574–4580.
   PubMed Web of Science ®Google Scholar
• Adamson RT. Biomarkers and molecular profiling in non-small cell lung cancer: an expanding role and its managed care implications. Am J Manag Care. 2013;19:398–04.
   Google Scholar
• Gandhi J, Zhang J, Xie Y, et al. Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. PLoS One. 2009;4:1–11.
   Web of Science ®Google Scholar
• Luk PP, Yu B, Ng CC, et al. BRAF mutations in non-small cell lung cancer. Transl Lung Cancer Res. 2015;4:142–148.
   PubMed Web of Science ®Google Scholar
• Angulo B, Conde E, Suárez-Gauthier A, et al. A comparison of EGFR mutation testing methods in lung carcinoma: direct sequencing, real-time PCR and immunohistochemistry. PLoS One. 2012;7:1–12.
   Web of Science ®Google Scholar
• Ellison G, Zhu G, Moulis A, et al. EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples. J Clin Pathol. 2013;66:79–89.
   PubMed Web of Science ®Google Scholar
• Liu X, Lu Y, Zhu G, et al. The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced non-small cell lung cancer: comparison of methodologies. J Clin Pathol. 2013;66(12):1065–1069.
   PubMed Web of Science ®Google Scholar
• Wu YC, Chang IC, Wang CL, et al. Comparison of IHC, FISH and RT-PCR methods for detection of ALK rearrangements in 312 non-small cell lung cancer patients in Taiwan. PLoS One. 2013;8:1–8.
   Google Scholar
• Sudhindra A, Ochoa R, Santos ES. Biomarkers, prediction, and prognosis in non–small-cell lung cancer: a platform for personalized treatment. Clin Lung Cancer. 2011;12(6):360–368.
   PubMed Web of Science ®Google Scholar
• Patel JN, Ersek JL, Kim ES. Lung cancer biomarkers, targeted therapies and clinical assays. Transl Lung Cancer Res. 2015;4:503–514.
   PubMedGoogle Scholar
• Lovly CM. Combating acquired resistance to tyrosine kinase inhibitors in lung cancer. Am Soc Clin Oncol. 2015;35:165–173.
   Google Scholar
• Greulich H. The genomics of lung adenocarcinoma: opportunities for targeted therapies. Genes Cancer. 2010;1(12):1200–1210.
   PubMedGoogle Scholar
• Naidoo J, Drilon A. Molecular diagnostic testing in non-small cell lung cancer. Am J Hematol Oncol. 2014;10:4–11.
   Google Scholar
• Bronte G, Rizzo S, La Paglia L, et al. Driver mutations and differential sensitivity to targeted therapies: A new approach to the treatment of lung adenocarcinoma. Cancer Treat Rev. 2010;36:21–29.
   PubMed Web of Science ®Google Scholar
• Westcott PMK, To MD. The genetics and biology of KRAS in lung cancer. Chin J Cancer. 2013;32(2):63–70.
   PubMed Web of Science ®Google Scholar
• Chung C, Christianson M. Predictive and prognostic biomarkers with therapeutic targets in breast, colorectal, and non-small cell lung cancers: A systemic review of current development, evidence, and recommendation. J Oncol Pharm Pract. 2014;20(1):11–28.
   PubMedGoogle Scholar
• Chakrabarti G. Mutant KRAS associated malic enzyme 1 expression is a predictive marker for radiation therapy response in non-small cell lung cancer. Radiat Oncol. 2015;10(1):145–152.
   PubMed Web of Science ®Google Scholar
• Xia Y, Liu Y-L, Xie Y, et al. A combination therapy for KRAS-driven lung adenocarcinomas using lipophilic bisphosphonates and rapamycin. Sci Transl Med. 2010;6:1203–1214.
   Google Scholar
• Vasan N, Boyer JL, Herbst RS. A RAS renaissance: emerging targeted therapies for KRAS-mutated non-small cell lung cancer. Clin Cancer Res. 2014;20:3921–3930.
   PubMed Web of Science ®Google Scholar
• Byron E, Pinder-Schenck M. Systemic and targeted therapies for early-stage lung cancer. Cancer Control. 2014;21:21–31.
   PubMed Web of Science ®Google Scholar
• Felip E, Á C, De Castro J, et al. Biomarker testing in advanced non-small-cell lung cancer: a national consensus of the Spanish society of pathology and the Spanish society of medical oncology. Clin Transl Oncol. 2015;17:103–112.
   PubMed Web of Science ®Google Scholar
• Campos-Gomez S, Lara-Guerra H, Routbort M, et al. Lung adenocarcinoma with concurrent KRAS mutation and ALK rearrangement responding to crizotinib: case report. Int J Biol Markers. 2015;30:254–257.
   Web of Science ®Google Scholar
• Boutin C, Rey F, Gouvernet J, et al. Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 1: diagnosis. Cancer. 1993;72:394–04.
   PubMed Web of Science ®Google Scholar
• Jänne PA, Smith I, McWalter G, et al. Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer. Br J Cancer. 2015;113:199–03.
   PubMed Web of Science ®Google Scholar
• Eccles SA, Massey A, Raynaud FI, et al. NVP-AUY922: A novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res. 2008;68:2850–2860.
   PubMed Web of Science ®Google Scholar
• Kelly K, Nawrocki S, Mita A, et al. Reovirus-based therapy for cancer. Expert Opin Biol Ther. 2009;9:817–830.
   PubMed Web of Science ®Google Scholar
• NCIC Clinical Trials Group. ClinicalTrials.gov Identifier: NCT01708993 [Internet]. [cited 2015 Dec 3]. Available from: https://clinicaltrials.gov/ct2/show/NCT01708993.
   Google Scholar
• [cited 2015 Dec 3]. Available from: http://www.oncolyticsbiotech.com/reolysin/clinical-trials/.
   Google Scholar
• Kwak EL, Bang Y-J, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363:1693–03.
   PubMed Web of Science ®Google Scholar
• Iacono D, Chiari R, Metro G, et al. Future options for ALK-positive non-small cell lung cancer. Lung Cancer. 2015;87:211–219.
   PubMed Web of Science ®Google Scholar
• Padda S, Neal JW, Wakelee HA. MET inhibitors in combination with other therapies in non-small cell lung cancer. Transl Lung Cancer Res. 2012;1:238–253.
   PubMedGoogle Scholar
• Sgambato A, Casaluce F, Maione P, et al. The c-Met inhibitors: a new class of drugs in the battle against advanced nonsmall-cell lung cancer. Curr Pharm Des. 2012;18:6155–6168.
   PubMed Web of Science ®Google Scholar
• Lee C, Shiao H, Wang W, et al. Small-molecule EGFR tyrosine kinase inhibitors for the treatment of cancer. Expert Opin Investig Drugs. 2014;23:1333–1348.
   PubMed Web of Science ®Google Scholar
• Gray AL, Coleman DT, Castore RF, et al. Isothiocyanatostilbenes as novel c-Met inhibitors. Oncotarget. 2015;6:41180–41193.
   PubMed Web of Science ®Google Scholar
• Scagliotti G, Von Pawel J, Novello S, et al. Phase III multinational, randomized, double-blind, placebo-controlled study of tivantinib (ARQ 197) plus erlotinib versus erlotinib alone in previously treated patients with locally advanced or metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol. 2015;33:1–8.
   PubMed Web of Science ®Google Scholar
• Menis J, Levra MG, Novello S. MET inhibition in lung cancer. Transl Lung Cancer Res. 2013;2:23–39.
   PubMedGoogle Scholar
• Goździk-Spychalska J, Szyszka-Barth K, Ł S, et al. c-MET inhibitors in the treatment of lung cancer. Curr Treat Options Oncol. 2014;15:670–682.
   PubMed Web of Science ®Google Scholar
• Gerber DE, Gandhi L, Costa DB. Management and future directions in non-small cell lung cancer with known activating mutations. Am Soc Clin Oncol Educ B. 2014;15:353–365.
   Google Scholar
• Heideman DAM, Lurkin I, Doeleman M, et al. KRAS and BRAF mutation analysis in routine molecular diagnostics. J Mol Diagn. 2012;14:247–255.
   PubMed Web of Science ®Google Scholar
• Huang L, Fu L. Mechanisms of resistance to EGFR tyrosine kinase inhibitors. Acta Pharm Sin B. 2015;5(5):390–391.
   PubMed Web of Science ®Google Scholar
• Gautschi O, Pauli C, Strobel K, et al. A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib. J Thorac Oncol. 2012;7:23–24.
   PubMed Web of Science ®Google Scholar
• Rudin CM, Hong K, Streit M. Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer. J Thorac Oncol. 2013;8:41–42.
   PubMed Web of Science ®Google Scholar
• Joshi M, Rice SJ, Liu X, et al., . Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer. PLoS One. 2015;10(2):1–13.
   Web of Science ®Google Scholar
• Davies KD, Le AT, Theodoro MF, et al. Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin Cancer Res. 2012;18(17):4570–4579.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Ou S-HI, Bang Y-J, et al. Crizotinib in ROS1 -rearranged non–small-cell lung cancer. N Engl J Med. 2014;371:1963–1971.
   PubMed Web of Science ®Google Scholar
• Mazières J, Zalcman G, Crinò L, et al. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. J Clin Oncol. 2015;33:992–999.
   PubMed Web of Science ®Google Scholar
• D’Arcangelo M, D’Incecco A, Cappuzzo F. Rare mutations in non-small-cell lung cancer. Futur Oncol. 2013;9(5):699–11.
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Krzakowski M, Szczesna A, et al. Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: A phase III trial. J Clin Oncol. 2012;30:2070–2078.
   PubMed Web of Science ®Google Scholar
• Morabito A, Piccirillo MC, Costanzo R, et al. Vandetanib: an overview of its clinical development in NSCLC and other tumors. Drugs of Today. 2010;46:683–698.
   PubMed Web of Science ®Google Scholar
• De Boer RH, Ó A, Yang C-H, et al. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2011;29:1067–1074.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Sun Y, Eberhardt W, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol. 2010;11:619–626.
   PubMed Web of Science ®Google Scholar
• Lee JS, Hirsh V, Park K, et al. Vandetanib versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol. 2012;30:1114–1121.
   PubMed Web of Science ®Google Scholar
• Natale RB, Thongprasert S, Greco FA, et al. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non - small-cell lung cancer. J Clin Oncol. 2011;29:1059–1066.
   PubMed Web of Science ®Google Scholar
• Califano R, Abidin A, Tariq NUA, et al. Beyond EGFR and ALK inhibition: unravelling and exploiting novel genetic alterations in advanced non-small-cell lung cancer. Cancer Treat Rev. 2015;41:401–411.
   PubMed Web of Science ®Google Scholar
• Drilon A, Wang L, Hasanovic A, et al. Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov. 2013;3:630–635.
   PubMed Web of Science ®Google Scholar
• Karp DD, Paz-Ares LG, Novello S, et al. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol. 2009;27:2516–2522.
   PubMed Web of Science ®Google Scholar
• Dearden S, Stevens J, Wu YL, et al. Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol. 2013;24:2371–2376.
   PubMed Web of Science ®Google Scholar
• Mogi A, Kuwano H. TP53 mutations in nonsmall cell lung cancer. J Biomed Biotechnol. 2011;2011:1–9.
   Google Scholar
• Jin G, Kim MJ, Jeon HS, et al. PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers. Lung Cancer. 2010;69:279–283.
   PubMed Web of Science ®Google Scholar
• Heist RS, L V S, Engelman JA. Genetic changes in squamous cell lung cancer: a review. J Thorac Oncol. 2012;7:924–933.
   PubMed Web of Science ®Google Scholar
• Fernandes AR, Baptista PV. Nanotechnology for cancer diagnostics and therapy – an update on novel molecular players. Curr Cancer Ther Rev. 2014;9:164–172.
   Google Scholar
• Collisson EA, Campbell JD, Brooks AN, et al. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511:543–550.
   PubMed Web of Science ®Google Scholar
• Richer AL, Friel JM, Carson VM, et al. Genomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR. Pharmgenomics Pers Med. 2015;8:63–79.
   PubMedGoogle Scholar
• Chan BA, Hughes BGM. Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl Lung Cancer Res. 2015;4:36–54.
   PubMed Web of Science ®Google Scholar
• Network TCGAR. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2014;489:519–525.
   Web of Science ®Google Scholar
• Ajnai G, Chiu A, Kan T, et al. Trends of gold nanoparticle-based drug delivery system in cancer therapy. J Exp Clin Med. 2014;6:172–178.
   Google Scholar
• Díaz MR, Vivas-Mejia PE. Nanoparticles as drug delivery systems in cancer medicine: emphasis on RNAi-containing nanoliposomes. Pharmaceuticals. 2013;6(11):1361–1380.
   Google Scholar
• Kemp JA, Shim MS, Heo CY, et al. “Combo” nanomedicine: co-delivery of multi-modal therapeutics for efficient, targeted, and safe cancer therapy. Adv Drug Deliv Rev. 2015. doi:10.1016/j.addr.2015.10.019.
   PubMed Web of Science ®Google Scholar
• Kumari P, Ghosh B, Biswas S. Nanocarriers for cancer-targeted drug delivery. J Drug Target. 2015. doi:10.3109/1061186X.2015.1051049.
   PubMed Web of Science ®Google Scholar
• Landesman-Milo D, Ramishetti S, Peer D. Nanomedicine as an emerging platform for metastatic lung cancer therapy. Cancer Metastasis Rev. 2015;10:291–01.
   Web of Science ®Google Scholar
• Egusquiaguirre SP, Igartua M, Hernández RM, et al. Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research. Clin Transl Oncol. 2012;14:83–93.
   PubMed Web of Science ®Google Scholar
• Sanna V, Pala N, Sechi M. Targeted therapy using nanotechnology: focus on cancer. Int J Nanomedicine. 2014;9:467–483.
   PubMed Web of Science ®Google Scholar
• Boisselier E, Astruc D. Gold nanoparticles in nanomedicine: preparations, imaging, diagnostics, therapies and toxicity. Chem Soc Rev. 2009;38(6):1759–1782.
   PubMed Web of Science ®Google Scholar
• Lammers T, Aime S, Hennink WE, et al. Theranostic nanomedicine. Acc Chem Res. 2011;44(10):1029–1038.
   PubMed Web of Science ®Google Scholar
• Parveen S, Misra R, Sahoo SK. Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. Nanomedicine Nanotechnology Biol Med. 2012;8(2):147–166.
   PubMed Web of Science ®Google Scholar
• Lee M, Lee S, Lee JH, et al. Highly reproducible immunoassay of cancer markers on a gold-patterned microarray chip using surface-enhanced Raman scattering imaging. Biosens Bioelectron. 2011;26(5):2135–2141.
   PubMed Web of Science ®Google Scholar
• Lin J, Chen R, Feng S, et al. A novel blood plasma analysis technique combining membrane electrophoresis with silver nanoparticle-based SERS spectroscopy for potential applications in noninvasive cancer detection. Nanomedicine. 2011;7:655–663.
   PubMed Web of Science ®Google Scholar
• Yuen C, Zheng W, Huang Z. Low-level detection of anti-cancer drug in blood plasma using microwave-treated gold-polystyrene beads as surface-enhanced Raman scattering substrates. Biosens Bioelectron. 2010;26(2):580–584.
   PubMed Web of Science ®Google Scholar
• Li S, Goins B, Zhang L, et al. A novel multifunctional theranostic liposome drug delivery system: construction, characterization, and multimodality MR, near-infrared fluorescent and nuclear imaging. Bioconjug Chem. 2012;23(6):1322–1332.
   PubMed Web of Science ®Google Scholar
• Kalia M. Personalized oncology: recent advances and future challenges. Metabolism. 2013;62:11–14.
   PubMed Web of Science ®Google Scholar
• Kircher MF, Hricak H, Larson SM. Molecular imaging for personalized cancer care. Mol Oncol. 2012;6:182–195.
   PubMed Web of Science ®Google Scholar
• Jin S-E, Jin H, Hong S. Targeted delivery system of nanobiomaterials in anticancer therapy: from cells to clinics. Biomed Res Int. 2014;2014:814208.
   Web of Science ®Google Scholar
• Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev. 2012;64:206–212.
   Web of Science ®Google Scholar
• Pillai G. Nanomedicines for cancer therapy: an update of FDA approved and those under various stages of development. SOJ Pharm Pharm Sci. 2014;1:1–13.
   Google Scholar
• Silva J, Fernandes AR, Baptista PV. Application of nanothechnology in drug delivery. In: Sezer AD, editor. Rijeka: InTech; 2014. Chapter 4, Application of nanotechnology in drug delivery; p. 127–154.
   Google Scholar
• Kasinski A, Kelnar K, Stahlhut C, et al. A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer. Oncogene. 2015;34(27):3547–3555.
   PubMed Web of Science ®Google Scholar
• Xue W, Dahlman JE, Tammela T, et al. Small RNA combination therapy for lung cancer. Proc Natl Acad Sci. 2014;111(34):E3553–61.
   PubMed Web of Science ®Google Scholar
• Schütz CA, Juillerat-Jeanneret L, Mueller H, et al. Therapeutic nanoparticles in clinics and under clinical evaluation. Nanomedicine. 2013;8(3):449–467.
   PubMed Web of Science ®Google Scholar
• Waheed A, Gupta A, Patel P. Targeted drug delivery systems for pancreatic cancer. PharmaTutor Mag. 2015;3:3462–3482.
   Google Scholar
• Coelho SC, Pereira MC, Juzeniene A, et al. Supramolecular nanoscale assemblies for cancer diagnosis and therapy. J Control Release. 2015;213:152–167.
   PubMed Web of Science ®Google Scholar
• Pedrosa P, Vinhas R, Fernandes A, et al. Gold nanotheranostics: proof-of-concept or clinical tool? Nanomaterials. 2015;5(4):1853–1879.
   Web of Science ®Google Scholar
• Martins P, Rosa D, Fernandes A, et al. Nanoparticle drug delivery systems: recent patents and applications in nanomedicine. Recent Patents Nanomed. 2014;3:105–118.
   Google Scholar
• Stinchcombe TE, Socinski MA, Lee CB, et al. Phase I trial of nanoparticle albumin-bound paclitaxel in combination with gemcitabine in patients with thoracic malignancies. J Thorac Oncol. 2008;3:521–526.
   PubMed Web of Science ®Google Scholar
• Werner ME, Cummings ND, Sethi M, et al. Preclinical evaluation of genexol-PM, a nanoparticle formulation of paclitaxel, as a novel radiosensitizer for the treatment of non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2013;86:463–468.
   PubMed Web of Science ®Google Scholar
• Zhang L, Gu F, Wang J, et al. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther. 2008;83:761–769.
   PubMed Web of Science ®Google Scholar
• Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Annu Rev Med. 2012;63(1):185–198.
   PubMed Web of Science ®Google Scholar
• Chakraborty C, Pal S, Doss GP, et al. Nanoparticles as “smart” pharmaceutical delivery. Front Biosci. 2013;18:1030–1050.
   Web of Science ®Google Scholar
• Desai N. Challenges in development of nanoparticle-based therapeutics. Aaps J. 2012;14(2):282–295.
   PubMed Web of Science ®Google Scholar
• Cho EJ, Holback H, Liu KC, et al. Nanoparticle characterization: State of the art, challenges, and emerging technologies. Mol Pharm. 2013;10:2093–2110.
   PubMed Web of Science ®Google Scholar
• Hofmann-Amtenbrink M, Grainger DW, Hofmann H. Nanoparticles in medicine: current challenges facing inorganic nanoparticle toxicity assessments and standardizations. Nanomedicine. 2015;11:1–6.
   Google Scholar